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Background
Although surgical resection for early stage lung cancer is 
the mainstay of treatment, many patients are inoperable at 
the time of presentation due to either disseminated disease 
or medical comorbidities (1). Novel strategies are currently 
being developed to treat early-stage non-small cell lung 
cancer (NSCLC) in this expanding population of high-
risk and inoperable patients. Stereotactic body radiotherapy 
(SBRT) modifies traditional radiation techniques to provide 
a high-dose per fraction of radiation to the tumor which is 
administered over a few fractions. This allows for effective 
tumor ablation with preservation of the surrounding tissue 
due to steep dose gradients. Radiofrequency ablation (RFA) 
utilizes CT-guided placement of a radiofrequency-emitting 
probe. As frictional heat energy from the probe is transferred 
to the tumor, cancer cells undergo coagulation necrosis. 
In an effort to expand the population of operable patients, 
many groups are currently exploring the use of sublobar 
resection to treat early stage tumors. Early evidence suggests 
that sublobar resection may provide satisfactory oncologic 
outcomes while avoiding the morbidity of standard lobectomy 
in patients with poor pulmonary reserve (2). Three major 
clinical trials have been developed to investigate the use of 
these different modalities to treat early stage lung cancer 
in inoperable or high-risk patients. A recently published 
trial, RTOG 0236, is a North American phase II trial of 
SBRT in patients with stage I NSCLC deemed inoperable 
by a surgeon or a pulmonologist. The study showed a 
local control rate of 90.6% at three years, and disease-free 
survival and overall survival at three years were 48.3% and 
55.8%, respectively (3). ACOSOG Z4032 is a phase III 
randomized controlled trial that compared sublobar resection 
to sublobar resection with brachytherapy for the treatment 
of stage I NSCLC. Thirty- and 90-day outcomes from this 
study have recently been published (4). In addition, three-
year results were presented at the 2013 American Society of 
Clinical Oncology (ASCO) meeting, showing a similar rate 
of local recurrence for those treated with sublobar resection 
(12.8%) versus sublobar resection with brachytherapy 
(12.5%) (5). Overall survival was comparable between the 
groups (sublobar resection =71%, sublobar resection with 
brachytherapy =72%). Lastly, ACOSOG Z4033 is a phase 
II prospective nonrandomized study examining high-risk 
patients with stage I NSCLC treated with RFA. This study 
has completed accrual, but survival and recurrence data have 
not yet matured. We conducted a comparison of selection 
criteria and short-term outcomes for these three studies.
Patients and setting
Patients
This study focuses on patients with stage I lung cancer that 
are high risk for surgical intervention due to medical co-
morbidities.
Intervention(s)
We explore the selection criteria and short-term outcomes 
in high risk patients treated with three different treatment 
modalities: SBRT, sublobar resection, and RFA.
Objective(s)
We sought to compile data from three major North 
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American trials in order to compare the selection of 
patients for these three treatment options, and to provide 
some insight into the short-term morbidity and mortality 
associated with each.
Methodology
The study was a retrospective secondary analysis of 
prospectively collected data from three multicenter trials 
(RTOG trial 0236, ACOSOG trial Z4032, and ACOSOG 
Z4033). The data were formally requested from the RTOG 
and ACOSOG, and the analysis was approved by both 
organizations. We compared entry criteria and short-term 
outcomes using raw data from all three trials. Categorical 
data were compared using chi-square test and continuous 
data using the Kruskal-Wallis test. We then performed 
a propensity-matched analysis of patients treated with 
SBRT and sublobar resection (RTOG 0236 and ACOSOG 
Z4032). Variables including age, Eastern Cooperative 
Oncology Group (ECOG) performance status, percentage 
of predicted forced expiratory volume in one second 
(FEV1%), and percentage of predicted carbon monoxide 
diffusing capacity of the lung (DLCO%) were used to 
build a propensity score for patients with clinical stage IA 
NSCLC. These scores were developed to estimate the 
adjusted risks of short-term outcomes associated with the 
choice of treatment (SBRT or surgery).
Primary outcomes
Main results
There were 55 patients available for analysis from RTOG 
0236 (SBRT), 211 from ACOSOG Z4032 (sublobar 
resection), and 51 from ACOSOG Z4033 (RFA). RFA 
patients were older than those undergoing sublobar 
resection or SBRT (mean age in years =75.6, 70.2, 72.5 
respectively, P=0.02) (Table 1). Despite having been 
identified as medically inoperable according to study 
criteria, SBRT patients had superior DLCO% (61.6%) 
compared with sublobar resection (46.4%) and RFA (43.7%) 
(P=0.001). All patients had either T1 or T2 tumors. 
Twenty percent of patients treated with SBRT had T2 
Table 1 Pre-treatment demographics and comorbidity profiles for RTOG 0236, ACOSOG Z4032, and ACOSOG Z4033
Pre-treatment characteristics RTOG 0236 (SBRT)





N 55 211 51
Age (mean) 72.5±8.8 70.2±8.5 75.6±7.5 0.00031
Age >75 21 (38.9%) 79 (37.4%) 30 (58.8%) 0.022
Female 34 (61.8%) 117 (55.5%) 28 (54.9%) 0.7
ECOG 1-2 43 (78.1%) 169 (80.1%) 42 (82.4%) 0.86
Race (white) 51 (92.7%) 199 (94.3%) 44 (86.3%) 0.023
Clinical stage IA 44 (80%) 208 (98.6%) 51 (100%) <0.00014
Pulmonary hypertension NR 5 (2.4%) 1 (2.0%) 0.86
Poor LV function NR 12 (5.7%) 6 (11.8%) 0.12
MMRC dyspnea score NR 46 (21.8%) 12 (23.5%) 0.79
pO2 ≤55 mmHg or SpO2 ≤88% 2 (3.7%) 10 (4.7%) 1 (2.0%) 0.66
pCO2 >45 mmHg 8 (14.8%) 6 (2.8%) 0 0.0002
5
DLCO% 61.6±30.2 46.4±15.6 43.7±18.0 0.0016
FEV1% 61.3±33.4 53.8±19.6 48.8±20.3 0.15
FVC% 79.8±23.2 74.8±17 NR 0.4
Values are mean ± SD or n (%) as appropriate. P-values are from Chi-square or Kruskall-Wallis test. NR, not reported; 1, P<0.0001 
Z4032 vs. Z4033; 2, P=0.04 RTOG 0236 vs. Z4033, P=0.005 Z4032 vs. Z4033; 3, P=0.04 RTOG 0236 vs. Z4032; 4, P<0.0001 RTOG 
vs. Z4032, P=0.0007 RTOG 0236 vs. Z4033; 5, P=0.0004 RTOG 0236 vs. Z4032, P=0.004 RTOG 0236 vs. Z4033; 6, P=0.0008 
RTOG0236 vs. Z4032, P=0.001 RTOG 0236 vs. Z4033. ECOG, Eastern Cooperative Oncology Group; DLCO%, diffusing capacity 
of the lung; FEV1%, forced expiratory volume in one second.
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disease (n=11), compared with 1.4% of those treated with 
sublobar resection (n=3). All patients treated with RFA had 
T1 tumors. SBRT patients received an average of 60 Gy 
of radiation.  In patients undergoing surgical resection for 
clinical stage IA disease, 29.3% ultimately had a higher 
stage on final pathology (pIB in 25%, pIIA in 0.5%, pIIB in 
1.6%, pIIIA in 1.1%, pIIIB in 0.5%, and IV in 1.1%).
Thirty- and 90-day outcomes are shown in Table 1. 
For RFA, only mortality data were available. There was 
no significant difference in 30-day, 90-day, or treatment-
related mortality amongst the three modalities. There was, 
however, a higher incidence of grade 3+ events at 30 days in 
patients undergoing sublobar resection (28.0%) compared 
with SBRT (9.1%) (P=0.004). The incidence was equivalent 
at 90 days (33.2% for sublobar resection, and 21.8% for 
SBRT, P=0.24). A propensity-matched score was then used 
to compare SBRT (n=44) and sublobar resection (n=208) 
in patients with T1 lesions. In the propensity-matched 
analysis, there was no difference in 30- or 90-day grade 3+ 
adverse events between these two modalities. An additional 
analysis was performed examining pre- and post-treatment 
DLCO% and FEV1% in patients treated with SBRT 
and sublobar resection. After adjusting for pre-treatment 
values, there was no difference in DLCO%. However, post-
treatment FEV1% was 6.4% greater in patients undergoing 
sublobar resection compared with those treated with SBRT.
Study limitations
Although each of the trials was designed to evaluate patients 
with early stage lung cancer, subtle underlying differences 
in the patient populations exist. Similarly, as long-term data 
has not yet matured, we cannot comment on the oncologic 
efficacy of the treatments. In addition, our propensity 
matched comparison may be underpowered to detect 
differences in morbidity and mortality. The current analysis 
was meant to provide preliminary insight and definite 
conclusions will best be made using specifically designed, 
randomized controlled data comparing the modalities 
directly.
Applicability to other populations
These trials were designed to evaluate treatment of early 
stage lung cancer in high-risk or non-operable patients. The 
data are not necessarily applicable to patients with more 
advanced disease or to those who are satisfactory operative 
candidates.
Conclusions
Variability in patient populations in these three studies 
underscores the need for more reliable, objective criteria to 
identify the inoperable patient, the high risk but potentially 
operable patient, and the very high risk patient that may 
have a relatively better risk/benefit ratio from non-operative 
therapy vs. operative therapy. Our propensity-matched 
analysis of high-risk or inoperable patients with clinical 
stage I lung cancer shows no difference in 30- or 90-day 
mortality and morbidity between SBRT and sublobar 
resection. These results emphasize the need for specifically 
designed randomized trials to compare these treatment 
modalities and further stratify patients considered high risk.
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